New products
Over half of target patients enrolled in Xeltis’ aXess US pivotal trial
Xeltis has enrolled over 50% of target patients in its US pivotal trial for aXess, a vascular access device for adults with end-stage renal disease requiring hemodialysis. The milestone marks progress toward regulatory submission for the device.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network